Fibronectin Inhibits Osteoclastogenesis While Enhancing Osteoclast Activity via Nitric Oxide and Interleukin-1β-Mediated Signaling Pathways

被引:24
作者
Gramoun, Azza [1 ]
Azizi, Natoosha [1 ]
Sodek, Jaro [1 ]
Heersche, Johan N. M. [1 ]
Nakchbandi, Inaam [2 ,3 ]
Manolson, Morris F. [1 ]
机构
[1] Univ Toronto, Fac Dent, Toronto, ON M5G 1G6, Canada
[2] Max Planck Inst Biochem, D-82152 Martinsried, Germany
[3] Heidelberg Univ, Inst Immunol, D-6900 Heidelberg, Germany
基金
加拿大健康研究院;
关键词
BONE; OSTEOCLAST; INTEGRIN; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTIN; OSTEOPONTIN; ACID-PHOSPHATASE; 5B; BONE-RESORPTION; GENE-EXPRESSION; SYNOVIAL-FLUID; SERUM MARKER; OSTEOPONTIN; RESISTANT; ARTHRITIS; SURFACE; VITRONECTIN;
D O I
10.1002/jcb.22791
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Osteoclasts are bone-resorbing cells formed by fusion of mononuclear precursors. The matrix proteins, fibronectin (FN), vitronectin (VN), and osteopontin (OPN) arc implicated in joint destruction and interact with osteoclasts mainly through integrins. To assess the effects of these matrix proteins on osteoclast formation and activity, we used RAW 264.7 (RAW) cells and mouse splenocytes differentiated into osteoclasts on tissue culture polystyrene (TCP) or osteologic (TM) slides pre-coated with 0.01-20 mu g/ml FN, VN, and OPN. At 96h, osteoclast number and multinucleation were decreased on VN and FN compared to OPN and TCP in both RAW and splenocytes cell cultures. When early differentiation was assessed, VN but not FN decreased cytoplasmic tartrate-resistant acid phosphatase activity and pre-osteoclast number at 48 h. OPN had the opposite effect to FN on osteoclast formation. When RAW cells were differentiated on OPN and treated by FN and OPN, osteoclast number only in the FN treated group was 40-60% lower than the control, while the total number of nuclei was unchanged, suggesting that EN delays osteoclast fusion. In contrast to its inhibitory effect on osteoclastogenesis, FN increased resorption by increasing both osteoclast activity and the percentage of resorbing osteoclasts. This was accompanied by an increase in nitric oxide (NO) levels and interleukin-1 beta (IL-1 beta). IL-1 beta production was inhibited using the NO-synthase inhibitor only on FN indicating a FN-specific cross-talk between NO and IL-1 beta signaling pathways. We conclude that FN upregulates osteoclast activity despite inhibiting osteoclast formation and that these effects involve NO and IL-1 beta signaling. J. Cell. Biochem. 111: 1020-1034, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:1020 / 1034
页数:15
相关论文
共 84 条
[71]
CD44 occupancy prevents macrophage multinucleation [J].
Sterling, H ;
Saginario, C ;
Vignery, A .
JOURNAL OF CELL BIOLOGY, 1998, 143 (03) :837-847
[72]
Sunyer T, 1996, J CELL BIOCHEM, V60, P469, DOI 10.1002/(SICI)1097-4644(19960315)60:4<469::AID-JCB4>3.0.CO
[73]
2-Q
[74]
Osteoimmunology and the effects of the immune system on bone [J].
Takayanagi, Hiroshi .
NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (12) :667-676
[75]
Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases [J].
Trebec, Diana P. ;
Chandra, Divya ;
Gramoun, Azza ;
Li, Keying ;
Heersche, Johan N. M. ;
Manolson, Morris F. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 101 (01) :205-220
[76]
Osteoclasts and giant cells: macrophage-macrophage fusion mechanism [J].
Vignery, A .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2000, 81 (05) :291-304
[77]
Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration [J].
Voronov, I ;
Heersche, JNM ;
Casper, RF ;
Tenenbaum, HC ;
Manolson, MF .
BIOCHEMICAL PHARMACOLOGY, 2005, 70 (02) :300-307
[78]
Osteopontin: Role in immune regulation and stress responses [J].
Wang, Kathryn X. ;
Denhardt, David T. .
CYTOKINE & GROWTH FACTOR REVIEWS, 2008, 19 (5-6) :333-345
[79]
Xu GW, 2005, J CLIN INVEST, V115, P1060
[80]
COOH-terminal heparin-binding fibronectin fragment induces nitric oxide production in rheumatoid cartilage through CD44 [J].
Yasuda, T ;
Kakinuma, T ;
Julovi, SM ;
Yoshida, M ;
Hiramitsu, T ;
Akiyoshi, M ;
Nakamura, T .
RHEUMATOLOGY, 2004, 43 (09) :1116-1120